| 11413285 |
PDE III inhibitors for treatment of asymptomatic heart failure |
Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar |
2022-08-16 |
| 10537588 |
Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
Olaf Joens, Rainer Kleemann |
2020-01-21 |
| 10117869 |
PDE III inhibitors for treatment of asymptomatic heart failure |
Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar |
2018-11-06 |
| 9889148 |
Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
Olaf Joens, Rainer Kleemann |
2018-02-13 |
| 9463199 |
Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
Olaf Joens, Rainer Kleemann |
2016-10-11 |
| 9375469 |
H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
Eric Martin Vaughn, Paulino Carlos Gonzalez-Hernandez |
2016-06-28 |
| 8980894 |
Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar |
2015-03-17 |
| 8883123 |
Use of vaccines for the treatment/prevention of the transmission of pathogens |
Eric Martin Vaughn |
2014-11-11 |
| 8664252 |
Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
Olaf Joens |
2014-03-04 |
| 8592558 |
H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
Eric Martin Vaughn, Paulino Carlos Gonzalez-Hernandez |
2013-11-26 |
| 8524701 |
Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
Brian Guth, Randolph Seidler |
2013-09-03 |
| 8202967 |
H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
Eric Martin Vaughn, Paulino Carlos Gonzalez-Hernandez |
2012-06-19 |
| 7208508 |
Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
Brian Guth, Randolph Seidler |
2007-04-24 |